Ciladopa

Today, Ciladopa has become a topic of great relevance and interest to a wide audience. Whether due to its impact on current society, its relevance in the historical context or its influence in the cultural sphere, Ciladopa is a topic that does not leave anyone indifferent. Over the years, it has sparked heated debates, fueled the curiosity of many, and been the subject of numerous studies and research. In this article, we will explore different aspects related to Ciladopa, analyzing its importance, its implications and its evolution over time. Without a doubt, Ciladopa is a topic that deserves our attention and reflection, so we hope that this reading will be interesting and enriching for all our readers.

Ciladopa
Clinical data
Other namesAY-27,110
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 2-{4-piperazin-1-yl}cyclohepta-2,4,6-trien-1-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H26N2O4
Molar mass370.449 g·mol−1
3D model (JSmol)
  • O=C3/C=C\C=C/C=C3/N2CCN(C(O)c1ccc(OC)c(OC)c1)CC2

Ciladopa (developmental code name AY-27,110) is a dopamine agonist with a similar chemical structure to dopamine.[1] It was under investigation as an antiparkinsonian agent but was discontinued due to concerns of tumorogenesis in rodents.[2][3][4][5]

References

  1. ^ Voith K (1985). "The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats". Psychopharmacology. 85 (4): 405–9. doi:10.1007/BF00429654. PMID 3927334. S2CID 1573473.
  2. ^ Koller WC, Fields JZ, Gordon JH, Perlow MJ (September 1986). "Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug". Neuropharmacology. 25 (9): 973–9. doi:10.1016/0028-3908(86)90190-5. PMID 3774130. S2CID 19175441.
  3. ^ Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J (1987). "A double-blind evaluation of ciladopa in Parkinson's disease". Movement Disorders. 2 (3): 211–7. doi:10.1002/mds.870020308. PMID 3332914. S2CID 31784301.
  4. ^ Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M (May 1987). "Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa". Neurology. 37 (5): 863–5. doi:10.1212/wnl.37.5.863. PMID 3574692. S2CID 25273606.
  5. ^ Lang AE (August 1987). "Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine"". The Canadian Journal of Neurological Sciences. 14 (3 Suppl): 474–82. doi:10.1017/s031716710003794x. PMID 3315148.